{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:00Z","timestamp":1791194520108,"version":"4.1.0"},"reference-count":231,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jocn.2014.01.016","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T08:23:14Z","timestamp":1404202994000},"page":"1835-1846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies"],"prefix":"10.1016","volume":"21","author":[{"given":"Simon A.","family":"Broadley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Boggild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Brew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.L.","family":"Macdonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron P.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Spies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Willoughby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2014.01.016_b0005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.016_b0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/01.WNL.0000094316.90240.EB","article-title":"Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985\u20132000","volume":"61","author":"Mayr","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1017\/S0317167100038798","article-title":"Measurement of health-related quality of life in multiple sclerosis patients","volume":"23","author":"Brunet","year":"1996","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0025","unstructured":"Access Economics Pty Ltd., Acting positively: strategic implications of the economic costs of MS in Australia: Multiple Sclerosis Research Australia; 2005."},{"key":"10.1016\/j.jocn.2014.01.016_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.1972.tb00111.x","article-title":"Multiple sclerosis: association with HL-A3","volume":"2","author":"Naito","year":"1972","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jocn.2014.01.016_b0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2014.01.016_b0040","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ng.2770","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","volume":"45","author":"International Multiple Sclerosis Genetics Consortium (IMSGC)","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jocn.2014.01.016_b0045","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/jnnp-2011-300174","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"82","author":"Lucas","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0050","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","article-title":"Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis","volume":"296","author":"Munger","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2014.01.016_b0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458513483889","article-title":"Childhood body mass index and multiple sclerosis risk: a long-term cohort study","volume":"19","author":"Munger","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0060","doi-asserted-by":"crossref","first-page":"e16149","DOI":"10.1371\/journal.pone.0016149","article-title":"Smoking and multiple sclerosis: an updated meta-analysis","volume":"6","author":"Handel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2014.01.016_b0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00019052-200206000-00001","article-title":"Pathogenesis of multiple sclerosis: an update on immunology","volume":"15","author":"Hemmer","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0070","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/brain\/110.6.1579","article-title":"The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study","volume":"110","author":"Ormerod","year":"1987","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2014.01.016_b0075","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1352458502008001155","article-title":"The natural history of secondary progressive multiple sclerosis: observations from the London study group","volume":"8","author":"Rice","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/brain\/122.4.625","article-title":"The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis","volume":"122","author":"Cottrell","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2014.01.016_b0090","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2014.01.016_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jns.2009.07.017","article-title":"Statistical methods for the analysis of relapse data in MS clinical trials","volume":"285","author":"Wang","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0100","first-page":"153","article-title":"Measurement of disability in multiple sclerosis","volume":"13","author":"Gray","year":"2008","journal-title":"Neurol Asia"},{"key":"10.1016\/j.jocn.2014.01.016_b0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.nic.2008.06.008","article-title":"The use of MR imaging as an outcome measure in multiple sclerosis clinical trials","volume":"18","author":"Bermel","year":"2008","journal-title":"Neuroimaging Clin N Am"},{"key":"10.1016\/j.jocn.2014.01.016_b0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00234-009-0645-1","article-title":"Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis","volume":"52","author":"van den Elskamp","year":"2010","journal-title":"Neuroradiology"},{"key":"10.1016\/j.jocn.2014.01.016_b0115","unstructured":"Product Information Search Page. Australian Governement, 2013. Available from: https:\/\/www.ebs.tga.gov.au\/ [accessed 02\/05\/2013, 2013]."},{"key":"10.1016\/j.jocn.2014.01.016_b0120","unstructured":"Pharmaceutical Benefits Scheme. Australian Government, 2013. Available from: http:\/\/www.pbs.gov.au\/pbs\/home [accessed 02\/05\/2013, 2013]."},{"key":"10.1016\/j.jocn.2014.01.016_b0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ncl.2011.01.003","article-title":"Promising emerging therapies for multiple sclerosis","volume":"29","author":"Giovannoni","year":"2011","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jocn.2014.01.016_b0130","doi-asserted-by":"crossref","first-page":"740505","DOI":"10.1155\/2011\/740505","article-title":"Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis","volume":"2011","author":"Khan","year":"2011","journal-title":"Neurol Res Int"},{"key":"10.1016\/j.jocn.2014.01.016_b0135","unstructured":"Marie P, Lubbock M. Lectures on Diseases of the Spinal Cord. London: Sydenham Society; 1895; London. p. 134-6, 53."},{"key":"10.1016\/j.jocn.2014.01.016_b0140","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1055\/s-0028-1165510","article-title":"Uber antimonbehandlung der multiple Sklerose","volume":"54","author":"Crecelius","year":"1928","journal-title":"Deutsche med Wchnschr"},{"key":"10.1016\/j.jocn.2014.01.016_b0145","series-title":"Textbook of Pharmacology and Therapeutics","author":"Cushny","year":"1910"},{"key":"10.1016\/j.jocn.2014.01.016_b0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(53)91130-1","article-title":"Disseminated sclerosis; assessment of the effect of treatment on the course of the disease","volume":"265","author":"Compston","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.016_b0155","first-page":"336","article-title":"Diathermy in the treatment of multiple sclerosis","volume":"44","author":"Stephenson","year":"1926","journal-title":"Physical Therapy"},{"key":"10.1016\/j.jocn.2014.01.016_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF01680490","article-title":"Vier jahne malariabehandlung der multiplen Sklerose","volume":"111","author":"Dreyfus","year":"1929","journal-title":"Deutsche Z Nervenheilkd"},{"key":"10.1016\/j.jocn.2014.01.016_b0165","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archneurpsyc.1935.02250180094005","article-title":"Quinine therapy in cases of multiple sclerosis over a five year period","volume":"33","author":"Brickner","year":"1935","journal-title":"Arch Neurol Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0170","first-page":"429","article-title":"Les injections intraveineuses de salicylate de soude dans le traitement de la scl\u00e9rose en plaques","volume":"33","author":"Foix","year":"1926","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)60085-0","article-title":"The treatment of disseminated sclerosis: a suggestion","volume":"117","author":"Buzzard","year":"1911","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.016_b1160","series-title":"Text-book of nervous diseases for physicians and students","author":"Oppenheim","year":"1911"},{"key":"10.1016\/j.jocn.2014.01.016_b0185","series-title":"The case of Augustus d\u2019Est","author":"Firth","year":"1948"},{"key":"10.1016\/j.jocn.2014.01.016_b0190","first-page":"560","article-title":"A specific vaccine treatment of disseminated sclerosis","volume":"1","author":"Purves-Stewart","year":"1930","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.jocn.2014.01.016_b0195","first-page":"591","article-title":"The Aetiology of Disseminate Sclerosis: some criticisms of recent work, especially with regard to the \u201cSpherula Insularis\u201d","volume":"24","author":"Carmichael","year":"1931","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneurpsyc.1947.02300240017001","article-title":"Results of treatment of multiple sclerosis with dicoumarin","volume":"57","author":"Putnam","year":"1947","journal-title":"Arch Neurol Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b1165","series-title":"Multiple sclerosis","author":"McAlpine","year":"1955"},{"key":"10.1016\/j.jocn.2014.01.016_b0210","first-page":"800","article-title":"Treatment of multiple sclerosis by the intravenous administration of histamine","volume":"124","author":"Horton","year":"1944","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2014.01.016_b0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02124822","article-title":"Treatment of multiple sclerosis with anti-measles cow colostrum","volume":"173","author":"Ebina","year":"1984","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0220","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0002-8223(21)03331-9","article-title":"Hyperimmune bovine colostrum inefficacious as multiple sclerosis therapy in double-blind study","volume":"87","author":"Bayard","year":"1987","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jocn.2014.01.016_b0225","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1212\/WNL.41.7.1047","article-title":"An open trial of OKT3 in patients with multiple sclerosis","volume":"41","author":"Weinshenker","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0230","first-page":"198","article-title":"Treatment of multiple sclerosis with 15 +\/\u2212 deoxyspergualin. Design of a controlled study with close MRI-monitoring","volume":"144","author":"Kappos","year":"1993","journal-title":"Schweiz Arch Neurol Psychiatr"},{"key":"10.1016\/j.jocn.2014.01.016_b0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1172\/JCI118779","article-title":"Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients","volume":"98","author":"Fukaura","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2014.01.016_b0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.1997.tb48623.x","article-title":"Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis","volume":"835","author":"Hafler","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00868517","article-title":"Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study","volume":"243","author":"Lycke","year":"1996","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","article-title":"A randomized clinical trial of valacyclovir in multiple sclerosis","volume":"11","author":"Friedman","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0260","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-5728(97)00029-5","article-title":"Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide","volume":"76","author":"Gold","year":"1997","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0270","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1212\/WNL.49.2.351","article-title":"Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial","volume":"49","author":"van Oosten","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0275","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0009-9236(98)90183-7","article-title":"Phase I study of a humanized anti-CD11\/CD18 monoclonal antibody in multiple sclerosis","volume":"64","author":"Bowen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jocn.2014.01.016_b0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1212\/WNL.51.1.289","article-title":"Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS","volume":"51","author":"Calabresi","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0285","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1212\/WNL.51.5.1342","article-title":"The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis","volume":"51","author":"Noseworthy","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/135245859900500310","article-title":"A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis","volume":"5","author":"Rostami","year":"1999","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b1180","doi-asserted-by":"crossref","unstructured":"TTNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. he Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology 1999;53:457\u201365.","DOI":"10.1212\/WNL.53.3.457"},{"key":"10.1016\/j.jocn.2014.01.016_b0300","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/80525","article-title":"Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group","volume":"6","author":"Kappos","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0305","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83\u201399) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/135245850000600208","article-title":"Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials","volume":"6","author":"Tan","year":"2000","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s001150050636","article-title":"Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment","volume":"71","author":"Wiendl","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1016\/j.jocn.2014.01.016_b0320","first-page":"24","article-title":"A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients","volume":"8","author":"Frank","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.10301","article-title":"Treatment of multiple sclerosis with the pregnancy hormone estriol","volume":"52","author":"Sicotte","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jnnp.73.3.246","article-title":"A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the \u201cCari Loder regime\u201d) in the treatment of multiple sclerosis","volume":"73","author":"Wade","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0335","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0340","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejpain.2008.05.014","article-title":"Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis","volume":"13","author":"Conte","year":"2009","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.jocn.2014.01.016_b0345","first-page":"CD003057","article-title":"Hyperbaric oxygen therapy for multiple sclerosis","author":"Bennett","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0350","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1191\/1352458504ms1070oa","article-title":"Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1\/Th2 balance and NKT cell subset in multiple sclerosis","volume":"10","author":"Feng","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/13543784.13.3.215","article-title":"Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?","volume":"13","author":"Pershadsingh","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jocn.2014.01.016_b0360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1191\/1352458505ms1132oa","article-title":"A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis","volume":"11","author":"Baumhackl","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0365","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1126\/science.307.5716.1712","article-title":"Drug discovery. Magnificent obsession","volume":"307","author":"Couzin","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jocn.2014.01.016_b0370","unstructured":"Fieschi C, Andersen O, Markowitz C, et al. A phase II randomised, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of abatacept, a selective co-stimulation modulator, in patients with relapsing-remitting multiple sclerosis. In: 15th Meeting of the European Neurological Society; 2005 18\u201325 Jun 2005; Vienna."},{"key":"10.1016\/j.jocn.2014.01.016_b0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2005.03.042","article-title":"Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS","volume":"234","author":"Sriram","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0380","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1212\/01.wnl.0000184442.02551.4b","article-title":"A randomized crossover study of bee sting therapy for multiple sclerosis","volume":"65","author":"Wesselius","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/1352458505ms1143oa","article-title":"Lipoic acid in multiple sclerosis: a pilot study","volume":"11","author":"Yadav","year":"2005","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0390","first-page":"1326","article-title":"The evaluation of a novel \u201cgoat serum\u201d therapy (Aimspro) in multiple sclerosis","volume":"76","author":"Burke","year":"2006","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.jocn.2014.01.016_b0395","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1468-1331.2006.01533.x","article-title":"Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5years of follow-up treatment","volume":"13","author":"Warren","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0400","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0405","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/00003088-200746090-00003","article-title":"Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715","volume":"46","author":"Clucas","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jocn.2014.01.016_b0410","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0415","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"P\u00f6hlau","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0420","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archneurol.2007.41","article-title":"Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial","volume":"65","author":"Minagar","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0430","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/glycob\/cwm098","article-title":"A \u201cglyconutrient sham\u201d","volume":"18","author":"Schnaar","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.jocn.2014.01.016_b0435","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S0317167100008611","article-title":"Pilot study of minocycline in relapsing-remitting multiple sclerosis","volume":"35","author":"Zhang","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0445","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458508099141","article-title":"Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis","volume":"15","author":"Broadley","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0450","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clim.2009.01.005","article-title":"Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies","volume":"131","author":"Loftus","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0455","doi-asserted-by":"crossref","first-page":"e50478","DOI":"10.1371\/journal.pone.0050478","article-title":"T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial","volume":"7","author":"Karussis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2014.01.016_b0460","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0465","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0470","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0475","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"10.1016\/j.jocn.2014.01.016_b0480","first-page":"CD008386","article-title":"Statins for multiple sclerosis","author":"Wang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0485","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00415-012-6513-7","article-title":"Atorvastatin added to interferon \u03b2 for relapsing multiple sclerosis: a randomized controlled trial","volume":"259","author":"Kamm","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0490","first-page":"CD004192","article-title":"Dietary interventions for multiple sclerosis","volume":"12","author":"Farinotti","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0495","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneurol.2012.283","article-title":"\u03c9-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Torkildsen","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0500","first-page":"CD009903","article-title":"Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients","volume":"12","author":"van Zuuren","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0505","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0140-6736(13)61747-X","article-title":"Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study","volume":"383","author":"Traboulsee","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.016_b0510","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Avonex. Australia: TGA; 28 Jul 2009."},{"key":"10.1016\/j.jocn.2014.01.016_b0515","unstructured":"Biogen Idec NZ Ltd., Data Sheet \u2013 Avonex. Auckland, NZ: Medsafe; 22 Aug 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0520","unstructured":"Merck Serono Australia Pty Ltd., Product Information \u2013 Rebif. Australia: TGA; 15 Aug 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0525","unstructured":"Bayer Australia Limited. Product Information \u2013 Betaferon. Australia: TGA; 5 Nov 2010."},{"key":"10.1016\/j.jocn.2014.01.016_b0530","unstructured":"Bayer New Zealand Limited. Data Sheet \u2013 Betaferon. Auckland, NZ: Medsafe; 9 Aug 2010."},{"key":"10.1016\/j.jocn.2014.01.016_b0535","unstructured":"CSL Biotherapies (NZ) Limited. Data Sheet \u2013 Copaxone. Auckland, NZ: Medsafe; 1 Feb 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0540","unstructured":"CSL Limited. Product Information \u2013 Copaxone. Australia: TGA; 10 Apr 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0545","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Tysabri. Australia: TGA; 26 Nov 2010."},{"key":"10.1016\/j.jocn.2014.01.016_b0550","unstructured":"Biogen Idec NZ Ltd., Data Sheet \u2013 Tysabri. Auckland, NZ: Medsafe; 21 Nov 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0555","unstructured":"Novartis New Zealand Limited. Data Sheet \u2013 Gilenya. Auckland, NZ: Medsafe; 3 Sep 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0560","unstructured":"Novartis Pharmaceuticals Australia Pty Limited. Product Information \u2013 Gilenya. Australia: TGA; 11 Oct 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0565","unstructured":"Sanofi-Aventis Australia Pty Ltd., Product Information \u2013 Aubagio. Australia: TGA; 14 Nov 2012."},{"key":"10.1016\/j.jocn.2014.01.016_b0570","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Tecfidera. Australia: TGA; 21 Aug 2013."},{"key":"10.1016\/j.jocn.2014.01.016_b0575","unstructured":"Genzyme Corporation. Prescibing Information \u2013 Campath. US: FDA; 19 Sep 2007."},{"key":"10.1016\/j.jocn.2014.01.016_b0580","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.3390\/ijms131012665","article-title":"What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?","volume":"13","author":"Buzzard","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0585","first-page":"261","article-title":"Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro","volume":"15","author":"Rollinghoff","year":"1973","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0590","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2009.11.001","article-title":"Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA\/6-MP","volume":"218","author":"Aldinucci","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0595","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.39.8.1018","article-title":"A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis","volume":"39","author":"Ellison","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0600","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/WNL.41.1.20","article-title":"The efficacy of azathioprine in relapsing-remitting multiple sclerosis","volume":"41","author":"Goodkin","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0605","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02334408","article-title":"Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results","volume":"9","author":"Milanese","year":"1988","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0610","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00838165","article-title":"A double blind study on azathioprine efficacy in multiple sclerosis: final report","volume":"240","author":"Milanese","year":"1993","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0615","series-title":"Recent advances in multiple sclerosis therapy","first-page":"345","article-title":"Clinical controlled randomized trial of azathioprine in multiple sclerosis","author":"Ghezzi","year":"1989"},{"issue":"4","key":"10.1016\/j.jocn.2014.01.016_b0620","first-page":"CD003982","article-title":"Azathioprine for multiple sclerosis","author":"Casetta","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0625","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/archneur.62.12.1843","article-title":"Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging","volume":"62","author":"Massacesi","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0630","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-007-0842-9","article-title":"Azathioprine. Safety profile in multiple sclerosis patients","volume":"28","author":"La Mantia","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0635","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/WNL.46.6.1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study","volume":"46","author":"Confavreux","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0640","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.12041","article-title":"Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases","volume":"28","author":"van den Reek","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jocn.2014.01.016_b0645","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1191\/135248506ms1307cr","article-title":"Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis","volume":"12","author":"Putzki","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0650","first-page":"1286","article-title":"The mechanism of action of the folate antagonists in man","volume":"23","author":"Bertino","year":"1963","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jocn.2014.01.016_b0655","first-page":"CD003208","article-title":"Methotrexate for multiple sclerosis","author":"Gray","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0660","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0665","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudi\u00e9","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jocn.2014.01.016_b0670","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-011-1765-7","article-title":"Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review","volume":"30","author":"Rondon","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jocn.2014.01.016_b0675","first-page":"CD002819","article-title":"Cyclophosphamide for multiple sclerosis","author":"La Mantia","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jns.2004.04.022","article-title":"Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire","volume":"223","author":"Hommes","year":"2004","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0685","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2010.05.022","article-title":"High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report","volume":"296","author":"Nozaki","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0690","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00415-003-1089-x","article-title":"Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis","volume":"250","author":"Perini","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0695","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MJT.0b013e3181b3ad95","article-title":"High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863)","volume":"18","author":"Gladstone","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.jocn.2014.01.016_b0700","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00415-006-0154-7","article-title":"Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study","volume":"253","author":"Perini","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0705","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jocn.2014.01.016_b0710","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1756285609353354","article-title":"A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis","volume":"3","author":"Frohman","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2014.01.016_b0715","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285609355851","article-title":"A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)","volume":"3","author":"Remington","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2014.01.016_b0720","first-page":"1","article-title":"Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study","volume":"16","author":"Etemadifar","year":"2011","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0725","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1399-3062.2009.00407.x","article-title":"Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity","volume":"11","author":"Ritter","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jocn.2014.01.016_b0730","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jnnp-2013-305298","article-title":"Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients","volume":"85","author":"Michel","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0735","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2249.1992.tb05843.x","article-title":"Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone","volume":"90","author":"Baker","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0740","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0745","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0750","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.016_b0755","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/01.wnl.0000174439.70369.7a","article-title":"Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial","volume":"65","author":"Krapf","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0760","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp.2007.124958","article-title":"Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5year follow-up observational study of 100 consecutive patients","volume":"79","author":"Le Page","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0765","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1468-1331.2007.01969.x","article-title":"Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up","volume":"14","author":"Buttinelli","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0770","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458511398371","article-title":"Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study","volume":"17","author":"Le Page","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0775","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/j.1552-4604.1995.tb05021.x","article-title":"Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis","volume":"35","author":"De Castro","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jocn.2014.01.016_b0780","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/GRF.0b013e3181f96cb1","article-title":"Use of hormonal protection for chemotherapy-induced gonadotoxicity","volume":"53","author":"Kim","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.jocn.2014.01.016_b0785","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2012-302235","article-title":"Increased risk of multiple sclerosis relapse after in vitro fertilisation","volume":"83","author":"Michel","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0790","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458508094882","article-title":"Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study","volume":"14","author":"Cocco","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0795","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00415-005-0839-3","article-title":"Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone","volume":"252","author":"Goffette","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0800","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1212\/WNL.59.6.954","article-title":"Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS","volume":"59","author":"Brassat","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0805","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","article-title":"Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0810","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1191\/1352458502ms836oa","article-title":"A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis","volume":"8","author":"Ghalie","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0815","first-page":"99","article-title":"Mitoxantrone-related acute leukemia in two MS patients","volume":"108","author":"Pielen","year":"2008","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.jocn.2014.01.016_b0820","doi-asserted-by":"crossref","unstructured":"Ellis RJ, Brown S, Boggild M. Therapy related acute leukaemia with mitoxantrone: 4years on, what is the risk and can it be limited? Association of British Neurologists joint meeting with the Royal College of Physicians; 23\u201324 Oct 2013; London.","DOI":"10.1136\/jnnp-2013-306573.28"},{"key":"10.1016\/j.jocn.2014.01.016_b0825","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/01.wnl.0000277703.74115.d2","article-title":"Interferon-beta: mechanism of action and dosing issues","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0830","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b1185","doi-asserted-by":"crossref","unstructured":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"10.1016\/j.jocn.2014.01.016_b0840","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.49.2.358","article-title":"Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"49","author":"Rudick","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1190","doi-asserted-by":"crossref","unstructured":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.","DOI":"10.1212\/WNL.43.4.655"},{"key":"10.1016\/j.jocn.2014.01.016_b0850","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","volume":"46","author":"Li","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0855","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0860","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.410430114","article-title":"Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group","volume":"43","author":"Simon","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0865","doi-asserted-by":"crossref","unstructured":"Placebo-controlled multicentre randomised trial of interferon beta-1b intreatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491\u20137.","DOI":"10.1016\/S0140-6736(98)10039-9"},{"key":"10.1016\/j.jocn.2014.01.016_b0870","first-page":"CD005181","article-title":"Interferon beta for secondary progressive multiple sclerosis","volume":"1","author":"La Mantia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b0875","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b0880","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0885","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","article-title":"Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial","volume":"8","author":"Kappos","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0890","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis: side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0895","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp.67.5.561","article-title":"Treatment recommendations for interferon-beta in multiple sclerosis","volume":"67","author":"Polman","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.016_b0900","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/WNF.0b013e3181f8d513","article-title":"Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis","volume":"33","author":"Fragoso","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2014.01.016_b0905","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/00002018-200427100-00005","article-title":"Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis","volume":"27","author":"Rieckmann","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.jocn.2014.01.016_b0910","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0915","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1212\/WNL.0b013e31822c90d7","article-title":"Interferon \u03b2-1b-neutralizing antibodies 5years after clinically isolated syndrome","volume":"77","author":"Hartung","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0920","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/NRL.0b013e3181de4924","article-title":"Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic","volume":"16","author":"Zarkou","year":"2010","journal-title":"Neurologist"},{"key":"10.1016\/j.jocn.2014.01.016_b0925","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1352458508099476","article-title":"Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis","volume":"15","author":"Ravnborg","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0930","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.63.11_suppl_5.S35","article-title":"Strategies for managing the side effects of treatments for multiple sclerosis","volume":"63","author":"Langer-Gould","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0935","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0940","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2012.7625","article-title":"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis","volume":"308","author":"Shirani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2014.01.016_b0945","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2012.13570","article-title":"Treatment with interferon beta for multiple sclerosis","volume":"308","author":"Goodin","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jocn.2014.01.016_b0950","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458506070620","article-title":"The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis","volume":"12","author":"Trojano","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.016_b0955","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1988.tb27100.x","article-title":"A suppressor cell line that prevents the adoptive transfer of EAE in Lewis rats","volume":"540","author":"Ellerman","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b0960","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.1090138","article-title":"Glatiramer acetate treatment of multiple sclerosis: an immunological perspective","volume":"186","author":"Racke","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b0965","doi-asserted-by":"crossref","first-page":"17992","DOI":"10.1073\/pnas.0909607106","article-title":"Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate","volume":"106","author":"Skihar","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocn.2014.01.016_b0970","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00415-008-1005-5","article-title":"Glatiramer acetate: evidence for a dual mechanism of action","volume":"255","author":"Blanchette","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0975","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0980","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O\u2019Connor","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b0985","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-1229(74)90012-9","article-title":"Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer","volume":"3","author":"Teitelbaum","year":"1974","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jocn.2014.01.016_b0990","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b0995","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b1000","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis","volume":"317","author":"Bornstein","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.54.4.813","article-title":"Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment","volume":"54","author":"Ge","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"Comi","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b1015","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jocn.2014.01.016_b1020","first-page":"CD004678","article-title":"Glatiramer acetate for multiple sclerosis","author":"La Mantia","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b1025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2014.01.016_b1035","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.173.6.1553","article-title":"Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules","volume":"173","author":"Bochner","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-065X.1990.tb00561.x","article-title":"Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions","volume":"114","author":"Hemler","year":"1990","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jocn.2014.01.016_b1045","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117519","article-title":"The pathophysiologic role of alpha 4 integrins in vivo","volume":"94","author":"Lobb","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2014.01.016_b1050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1065","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","article-title":"Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians","volume":"91","author":"Antonsson","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jocn.2014.01.016_b1070","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jocn.2014.01.016_b1075","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0165-6147(02)00012-3","article-title":"Linking Chinese medicine and G-protein-coupled receptors","volume":"24","author":"Im","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b1085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2007.04.053","article-title":"The immunomodulator FTY720 is phosphorylated and released from platelets","volume":"568","author":"Anada","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jocn.2014.01.016_b1090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2010.11.002","article-title":"Sphingosine-1-phosphate and immune regulation: trafficking and beyond","volume":"32","author":"Chi","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jocn.2014.01.016_b1095","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jocn.2014.01.016_b1100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2014.01.016_b1105","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jocn.2014.01.016_b1110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","article-title":"FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors","volume":"108","author":"Chiba","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jocn.2014.01.016_b1115","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200526218","article-title":"Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720","volume":"35","author":"Morris","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jocn.2014.01.016_b1120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.016_b1130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10354-012-0123-y","article-title":"Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group","volume":"162","author":"Fazekas","year":"2012","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.jocn.2014.01.016_b1135","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(11)70099-0","article-title":"Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study","volume":"10","author":"Khatri","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.016_b1140","unstructured":"FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). FDA; 2013. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm366529.htm [accessed 1 Nov 2013, 2013]."},{"key":"10.1016\/j.jocn.2014.01.016_b1145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","article-title":"Primary varicella zoster infection associated with fingolimod treatment","volume":"76","author":"Uccelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1150","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3182735d00","article-title":"Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod","volume":"79","author":"Ratchford","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.016_b1155","unstructured":"FDA Drug Safety Communication: safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod); 2011. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm284240.htm [accessed 8 Aug 2013, 2013]."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:16:34Z","timestamp":1760822194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586814001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":231,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0967586814001805"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.016","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2014 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}